Morgan Stanley upgraded Ionis Pharmaceuticals (IONS) to Overweight from Equal Weight with a price target of $62, up from $55.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Strong Financial Performance and Promising Prospects Justify Buy Rating
- Ionis Pharmaceuticals raises FY25 revenue view to $825M-$850M from $725M-$750M
- Ionis Pharmaceuticals reports Q2 EPS 70c, consensus 16c
- Barclays says Merck/AstraZeneca earnings neutral to Moderna, negative to Ionis
- IONS Earnings this Week: How Will it Perform?